Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments
- PMID: 18667021
- DOI: 10.1111/j.1749-0774.2008.00055.x
Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments
Abstract
Various animal models of bladder tumor have been developed for the preclinical evaluation of therapeutic modalities for the treatment of bladder cancers. The ideal model for the investigation of therapeutic effects of proposed novel intravesical treatments requires the mass of the implanted tumor to be confined to the urothelium of the bladder at least for the initial phase. However, previously reported bladder tumor models are not suitable for the evaluation of intravesical therapies for the treatment of superficial bladder cancer, since the muscle invasive tumors have developed from the beginnings of the experiments. These models are too aggressive to study local treatment effects. In the current study, we demonstrated that careful instillation of MBT-2 mouse bladder cancer cells into the bladder of a syngenic C3H/HeJ mouse could establish a superficial bladder tumor with an incidence of 100%. The procedure and technique for handling animals are simple for standard animal investigators. Maintenance of the in vitro conditions of MBT-2 cells without contamination of Mycoplasma and careful selection of the substrain of C3H mouse seem to be essential for stable tumor establishment. This bladder tumor model appeared to be easy to reproduce among several investigators in different institutions. The orthotopic bladder tumor model, which was confined to urothelium, lets us evaluate various intravesical treatment strategies.
Similar articles
-
Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.BMC Cancer. 2015 Apr 26;15:317. doi: 10.1186/s12885-015-1338-2. BMC Cancer. 2015. PMID: 25928041 Free PMC article.
-
EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse.Int J Urol. 2006 Oct;13(10):1344-6. doi: 10.1111/j.1442-2042.2006.01541.x. Int J Urol. 2006. PMID: 17010016
-
Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.Gene Ther. 2000 May;7(10):844-51. doi: 10.1038/sj.gt.3301157. Gene Ther. 2000. PMID: 10845722
-
Diagnosis and management of superficial bladder cancer.Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. doi: 10.1067/mcn.2001.117539. Curr Probl Cancer. 2001. PMID: 11514784 Review.
-
[Intravesical chemotherapy of superficial bladder tumors].Gan To Kagaku Ryoho. 1989 Feb;16(2):193-8. Gan To Kagaku Ryoho. 1989. PMID: 2645832 Review. Japanese.
Cited by
-
Potential role of transient receptor potential (TRP) channels in bladder cancer cells.J Physiol Sci. 2014 Jul;64(4):305-14. doi: 10.1007/s12576-014-0319-6. Epub 2014 May 22. J Physiol Sci. 2014. PMID: 24849279 Free PMC article.
-
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model.J Vis Exp. 2015 May 29;(99):e52743. doi: 10.3791/52743. J Vis Exp. 2015. PMID: 26068073 Free PMC article.
-
Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.Mol Ther. 2013 Mar;21(3):610-9. doi: 10.1038/mt.2012.269. Epub 2013 Jan 8. Mol Ther. 2013. PMID: 23295946 Free PMC article.
-
Experimental rat bladder urothelial cell carcinoma models.World J Urol. 2009 Jun;27(3):313-7. doi: 10.1007/s00345-009-0381-5. Epub 2009 Feb 15. World J Urol. 2009. PMID: 19219611 Free PMC article.
-
Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.BMC Cancer. 2015 Apr 26;15:317. doi: 10.1186/s12885-015-1338-2. BMC Cancer. 2015. PMID: 25928041 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical